Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
- Advertisement -
Recover your password.
A password will be e-mailed to you.
BENGALURU, India, Feb. 9, 2023 /PRNewswire/ — BAL Pharma Limited, a fully integrated pharmaceuticals Company specialising in Bulk Drugs, Prescription Drugs, Generics, and pharma intermediates, has announced its results for the quarter that ended December 31, 2022.
Financial Highlights (Standalone) – Q3 & 9MFY23
- Advertisement -
Particulars (₹ Mn) |
Q3FY23 |
Q3FY22 |
YoY |
9MFY23 |
9MFY22 |
YoY |
Revenue |
773.35 |
701.01 |
10.32 % |
2,228.43 |
2,091.53 |
6.55 % |
EBITDA |
70.76 |
72.13 |
-1.90 % |
194.77 |
222.64 |
-12.52 % |
PBT |
19.32 |
31.43 |
-38.51 % |
53.4 |
91.89 |
-41.89 % |
PAT |
14.70 |
12.17 |
20.78 % |
40.05 |
58.02 |
-30.97 % |
EPS |
0.94 |
0.82 |
14.63 % |
2.57 |
3.91 |
-34.27 % |
Financial Highlights
- Advertisement -
Formulations Business(FDF) – Revenue Driver
API Business – an integrated business model
Commenting on financial results, Mr. Shailesh Siroya, Managing Director, BAL Pharma, said,
“The Company showcased strong performance and incremental growth in this quarter. Our revenue grew by 10.32% YoY in Q3FY23. The performance of domestic formulations is exciting, registering an increase of 42.74% in Q3FY23. This accomplishment was achieved despite price fluctuations, margin pressure and hard-hitting market competition. We are constantly working towards improving our production efficiency and R&D process and are adopting all-around measures to sail through this turbulent time.
We are strategically enhancing our product portfolio and widening our geographical footprint to have better and deeper market penetration, increasing our market share in the API and Formulation segments. The Company has recently launched five new products in the export formulation segment and is planning to add more in the coming quarters.
In the long run, the medium and long-term opportunities look very promising. We are confident that our clear and consistent strategic vision will position us well to benefit from them. All our efforts are directed toward enhancing profitability and delivering good returns to the stakeholders.
Looking ahead, we have a strong order book position at ₹ 710 million, affording us confident revenue visibility for the rest of the year.”
About BAL Pharma Ltd (BPL)
Bal Pharma Limited (BSE: 524824; NSE: BALPHARMA) is a fully integrated pharmaceuticals Company specialising in Bulk Actives, Prescription Drugs, Generics and pharma intermediates. Bal Pharma’s focused therapeutic areas are Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. The Company is one of Gliclazide’s largest producers and exporters, a medicine to treat type-2 diabetes. Bal Pharma’s niche APIs and FDFs are produced at world-class manufacturing facilities in Karnataka, Maharashtra, Rajasthan and Uttarakhand. The Company exports APIs to Europe, Australia, Japan, the Far East, Canada, Latin America, Africa, the Middle East and other World markets. Its FDFs are exported to a Semi-regulated market, besides having a domestic presence. Backed by strength in Research and Development and robust infrastructure, Bal Pharma is poised to become a significant Company in the pharmaceutical industry.
Forward-Looking Statement:
Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. BAL Pharma Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
View original content:https://www.prnewswire.com/in/news-releases/bal-pharma-limited-showcased-strong-revenue-growth-for-q3–9mfy23-results-against-adverse-market-conditions-301742796.html
Get real time updates directly on you device, subscribe now.
- Advertisement -